Patents Represented by Attorney, Agent or Law Firm Carol A. Stratford
-
Patent number: 7034054Abstract: The present invention provides method for the treatment of a symptom of neuronal damage associated with cerebral ischemia comprising administering gamma-, beta-, or delta-tocopherol enriched tocopherol compositions.Type: GrantFiled: December 14, 2001Date of Patent: April 25, 2006Assignee: Galileo Pharmaceuticals, Inc.Inventors: Guy Miller, Lesley A. Brown, Ughetta Del Balzo, Stephen Flaim, Sekhar Boddupalli, Bing Wang
-
Patent number: 6653460Abstract: A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants.Type: GrantFiled: August 16, 2000Date of Patent: November 25, 2003Assignee: Elan Pharmaceuticals, Inc.Inventors: Robert Newcomb, Andrew L. Palma, Balazs G. Szoke, Katalin Tarczy-Hornoch, William F. Hopkins, Ruth L. Cong, George P. Miljanich, Robin Dean, Laszlo Nadasdi, Laszlo Urge, Stephen Scott Bowersox
-
Patent number: 6379882Abstract: A method of screening for and treating subjects with a therapeutically effective amount of a compound that is effective in reducing cellular damage related to an ischemic condition, such as stroke or glaucoma. Test compounds are selected and therapeutically effective amount determined based on the relative efficacy of test compounds in preventing cell death in primary cultures of excitable cells, such as retinal ganglion cells, in vitro.Type: GrantFiled: September 10, 1999Date of Patent: April 30, 2002Assignee: Elan Pharmaceuticals, Inc.Inventors: Catherine M. Bitler, Anke Meyer-Franke, Paul Wood
-
Patent number: 6329163Abstract: Compositions comprising a novel protease capable of cleaving &bgr;-amyloid precursor protein on the amino-terminal side of the &bgr;-amyloid peptide therein are provided. The protease is designated &bgr;-secretase. The &bgr;-secretase may be used in screening assays to identify &bgr;-secretase inhibitors, or the &bgr;-secretase is combined with a suitable polypeptide substrate and cleavage of the substrate determined in the presence and absence of the test substance.Type: GrantFiled: April 2, 1998Date of Patent: December 11, 2001Assignee: Elan Pharmaceuticals, Inc.Inventors: John P. Anderson, Kirsten L. Jacobson-Croak, Sukanto Sinha
-
Patent number: 6165977Abstract: Isozyme-specific agonists or activators of .epsilon.PKC are disclosed. The agonists include peptides corresponding to the region of .epsilon.PKC between about amino acids 85 and 92. Also disclosed are therapeutic methods employing such .epsilon.PKC-specific agonists to induce preconditioning and thereby reduce injury due to subsequent ischemia, as well as methods for screening test compounds for .epsilon.PKC-selective agonist properties.Type: GrantFiled: October 17, 1997Date of Patent: December 26, 2000Assignee: Board of Trustees of the Leland Stanford Junior UniversityInventor: Daria Mochly-Rosen
-
Patent number: 6156726Abstract: A novel class of peptides selectively block class E voltage-gated calcium channels. The class is exemplified by HG peptides such as HG-1, which is isolated from the venom-producing cells of the tarantula Hysterocrates gigas. Also disclosed are methods of producing blocking class E channels using the peptides. HG peptides have utility, for example, in inhibiting oxytocin release and for use as anticonvulsants.Type: GrantFiled: August 1, 1997Date of Patent: December 5, 2000Assignee: Elan Pharmaceuticals, Inc.Inventors: Robert Newcomb, Andrew L. Palma, Balazs G. Szoke, Katalin Tarczy-Hornoch, William F. Hopkins, Ruth L. Cong, George P. Miljanich, Robin Dean, Laszlo Nadasdi, Laszlo Urge, Stephen Scott Bowersox
-
Patent number: 6136786Abstract: A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.Type: GrantFiled: September 9, 1999Date of Patent: October 24, 2000Assignee: Elan Pharmaceuticals, Inc.Inventors: Alan Justice, Tejinder Singh, Kishor Chandra Gohil, Karen L. Valentino, George P. Miljanich
-
Patent number: 6114133Abstract: This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-.beta. peptide (x-.gtoreq.41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis.Type: GrantFiled: November 14, 1994Date of Patent: September 5, 2000Assignees: Elan Pharmaceuticals, Inc., Eli Lilly & CompanyInventors: Peter A. Seubert, Carmen Vigo-Pelfrey, Dale B. Schenk, Robin Barbour
-
Patent number: 6110471Abstract: A method of contraception by delivering to the ovaries of a female mammal a pharmaceutically-effective dose of a PDE3-specific inhibitor at about the time of ovulation.Type: GrantFiled: September 12, 1997Date of Patent: August 29, 2000Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marco Conti, Aaron J. W. Hsueh, Alexander Tsafriri
-
Patent number: 6054429Abstract: A improved method of treating pain is disclosed. The method includes administering to a subject an N-type voltage-sensitive calcium channel blocking omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. The method includes administering the omega conopeptide epidurally, preferably so that the compound is in prolonged or sustained contact with the epidural region.Type: GrantFiled: March 8, 1996Date of Patent: April 25, 2000Assignee: Elan Pharmaceuticals, Inc.Inventors: S. Scott Bowersox, Theresa Gadbois, Mark Raymond Pettus, Robert R. Luther
-
Patent number: 6015843Abstract: A method of preparing an aqueous suspension of organosilanized colloidal silica particles is disclosed. Such particles are used in a variety of applications including density gradient separation media, anti-abrasion coatings and toner materials. The disclosed process is environmentally safe and produces a product that is aqueous and non-toxic to most biological cells.Type: GrantFiled: January 14, 1998Date of Patent: January 18, 2000Assignee: Dendreon CorporationInventors: Peter Van Vlasselaer, Shirin W. Hasan
-
Patent number: 6001809Abstract: This invention provides peptides which block cellular adhesion mediated by VLA-4. The peptides can be used to treat a number of inflammatory diseases, in particular, inflammatory brain disorders.Type: GrantFiled: June 6, 1995Date of Patent: December 14, 1999Assignee: Elan Pharmaceuticals, Inc.Inventors: Eugene D. Thorsett, Theodore A. Yednock, Michael A. Pleiss
-
Patent number: 5998599Abstract: Disclosed is a novel gene and growth arrest gene product encoded by the gene. Expression of the growth arrest gene B4B results in inhibition of cellular proliferation. The gene and gene product serve as markers of cancerous or pre-cancerous conditions, and as markers of immune states.Type: GrantFiled: June 27, 1997Date of Patent: December 7, 1999Assignee: Dendreon CorporationInventors: Curtis L. Ruegg, Reiner Laus, Edgar G. Engleman
-
Patent number: 5994305Abstract: A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.Type: GrantFiled: August 21, 1998Date of Patent: November 30, 1999Assignee: Elan Pharmaceuticals, Inc.Inventors: Alan Justice, Tejinder Singh, Kishor Chandra Gohil, Karen L. Valentino, George P. Miljanich
-
Patent number: 5972716Abstract: An improved fluorescence monitoring apparatus for measuring fluorescent emission from a sample in response to sample irradiation by an emission beam is disclosed. The apparatus employs a sample tube having surface roughness characteristics which substantially reduce background fluorescence emission due to contamination of the tube holder in the apparatus. Also disclosed is a method of reducing such background, by texturing of a sample tube to produce desired roughness characteristics.Type: GrantFiled: December 5, 1995Date of Patent: October 26, 1999Assignee: The Perkin-Elmer CorporationInventors: Robert P. Ragusa, Timothy M. Woudenberg, Jeffrey M. Marmaro
-
Patent number: 5965361Abstract: A method for detecting the presence of a double-stranded target nucleic acid sequence contained in fixed cells or cell structures is provided. The method includes the steps of forming the fixed cells or cell structures by fixing cells or cell structures so as to allow a nucleic acid probe to enter, and forming a probe/RecA complex in which a single-stranded probe and RecA protein are stably bound to each other. The probe/RecA complex is allowed to react with the double-stranded target nucleic acid sequence to bind thereto under conditions in which the double-stranded target nucleic acid sequence is not denatured, and by detecting the RecA protein included in the probe/RecA complex, the presence of the double-stranded target nucleic acid sequence is detected.The invention provides a diagnostic method by which the position of a specific gene or its regulatory region in a chromosome and the presence of a nucleic acid sequence derived from virus can be measured or visualized with high sensitivity and with ease.Type: GrantFiled: October 30, 1995Date of Patent: October 12, 1999Assignee: Daikin Industries, Ltd.Inventors: Koji Kigawa, Mikayo Yamanaka, Kayo Kihara, Eli Mukai, Kazuaki Obata
-
Patent number: 5891849Abstract: A method of preventing progression of neuropathic pain is disclosed. The method includes administering to a subject an N-type voltage-sensitive calcium channel blocking compound which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are formulations effective to stabilize omega conotoxin peptide preparations at elevated temperatures. Novel omega conopeptides also form part of the invention.Type: GrantFiled: November 7, 1997Date of Patent: April 6, 1999Assignee: Elan Pharmaceuticals, Inc.Inventors: Gary Arthur Amstutz, Stephen Scott Bowersox, Kishorchandra Gohil, Peter Isadore Adriaenssens, Ramasharma Kristipati
-
Patent number: 5871933Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.Type: GrantFiled: June 7, 1995Date of Patent: February 16, 1999Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Kenneth G. Hadlock
-
Patent number: 5869241Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: GrantFiled: June 7, 1995Date of Patent: February 9, 1999Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
-
Patent number: 5859186Abstract: A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.Type: GrantFiled: July 3, 1996Date of Patent: January 12, 1999Assignee: Neurex CorporationInventors: Alan Justice, Tejinder Singh, Kishor Chandra Gohil, Karen L. Valentino, George P. Miljanich